TAKEDA PHARMACEUTICAL CO Business Summary

Takeda Pharmaceutical Co Ltd (TAK) operates as a global, R&D-driven biopharmaceutical leader, generating revenue through the discovery, manufacturing, and commercialization of innovative prescription medicines. The company’s diversified revenue stream is anchored by five core therapeutic areas: Gastroenterology (GI), Oncology, Neuroscience, Rare Diseases, and Plasma-Derived Therapies (PDT), supplemented by a growing Vaccines business. Its financial model is increasingly driven by "Growth and Launch Products," such as the blockbuster GI treatment Entyvio and the dengue vaccine Qdenga, which collectively account for over 50% of total revenue. Geographically, Takeda maintains a robust global footprint, with the United States serving as its largest market (contributing over 50% of sales), followed by Japan and the Europe/Canada region. Takeda currently ranks as the largest pharmaceutical company in Japan and a top-15 player globally, competing directly with industry titans such as AbbVie, Johnson & Johnson (Janssen), Pfizer, and Roche, while maintaining a competitive edge through its specialized focus on rare genetic diseases and complex plasma-derived therapies. Founded in 1781 by Chobei Takeda I in Osaka, Japan, the company has evolved from a traditional herbal shop into a multinational powerhouse, a transition accelerated by the landmark $62 billion acquisition of Shire in 2019. The current leadership team is headed by President and CEO Christophe Weber, who has led the company’s global transformation since 2014. In a significant succession move, Julie Kim—currently President of the U.S. Business Unit—has been named CEO-elect and is slated to succeed Weber in June 2026. Other key executives include Milano Furuta (Chief Financial Officer), Andrew Plump (President of R&D), and Gabriele Ricci (Chief Data & Technology Officer). The company is governed by a board chaired by Masami Iijima, with a high percentage of independent external directors including industry veterans like John Maraganore and Ian Clark. Takeda is publicly traded on the Tokyo and New York Stock Exchanges, with major institutional backing from entities such as BlackRock, The Vanguard Group, and The Master Trust Bank of Japan.